Zymeworks Analyst Ratings
Zymeworks Analyst Ratings
Zymeworks 分析師評
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | 6.81% | HC Wainwright & Co. | → $8 | Reiterates | Neutral → Neutral |
| 06/06/2023 | 6.81% | HC Wainwright & Co. | → $8 | Reiterates | Neutral → Neutral |
| 05/18/2023 | 140.32% | Citigroup | $17 → $18 | Maintains | Buy |
| 05/09/2023 | 153.67% | Stifel | $18 → $19 | Maintains | Buy |
| 03/31/2023 | 20.16% | JP Morgan | $8 → $9 | Maintains | Neutral |
| 03/21/2023 | 60.21% | Wells Fargo | → $12 | Assumes | → Overweight |
| 03/21/2023 | 6.81% | HC Wainwright & Co. | → $8 | Reiterates | → Neutral |
| 03/10/2023 | 126.97% | Citigroup | $21 → $17 | Maintains | Buy |
| 03/08/2023 | 113.62% | Guggenheim | → $16 | Reiterates | → Buy |
| 01/24/2023 | 6.81% | HC Wainwright & Co. | → $8 | Reiterates | → Neutral |
| 01/20/2023 | 33.51% | SVB Leerink | $8 → $10 | Maintains | Market Perform |
| 01/04/2023 | 6.81% | HC Wainwright & Co. | $10 → $8 | Maintains | Neutral |
| 12/22/2022 | 20.16% | Barclays | $7 → $9 | Maintains | Equal-Weight |
| 12/20/2022 | 46.86% | Jefferies | $7.7 → $11 | Upgrades | Hold → Buy |
| 11/21/2022 | 33.51% | HC Wainwright & Co. | $8 → $10 | Maintains | Neutral |
| 11/01/2022 | 6.81% | HC Wainwright & Co. | $40 → $8 | Downgrades | Buy → Neutral |
| 10/24/2022 | 140.32% | Stifel | $21 → $18 | Maintains | Buy |
| 10/21/2022 | 6.81% | SVB Leerink | $19 → $8 | Downgrades | Outperform → Market Perform |
| 10/04/2022 | 20.16% | Wells Fargo | $45 → $9 | Assumes | → Overweight |
| 09/14/2022 | 180.37% | Citigroup | $27 → $21 | Maintains | Buy |
| 08/26/2022 | 260.48% | Citigroup | $28 → $27 | Maintains | Buy |
| 05/27/2022 | 153.67% | SVB Leerink | $18 → $19 | Maintains | Outperform |
| 05/23/2022 | 434.05% | HC Wainwright & Co. | $44 → $40 | Maintains | Buy |
| 05/09/2022 | 273.83% | Citigroup | $30 → $28 | Maintains | Buy |
| 05/09/2022 | 273.83% | Citigroup | $30 → $28 | Maintains | Buy |
| 05/05/2022 | 86.92% | Guggenheim | → $14 | Upgrades | Neutral → Buy |
| 03/15/2022 | 100.27% | Evercore ISI Group | → $15 | Initiates Coverage On | → Outperform |
| 02/28/2022 | 300.53% | Citigroup | $53 → $30 | Maintains | Buy |
| 02/09/2022 | 540.85% | Wells Fargo | $56 → $48 | Maintains | Overweight |
| 12/10/2021 | 887.98% | Raymond James | → $74 | Downgrades | Strong Buy → Outperform |
| 12/10/2021 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 11/10/2021 | 260.48% | SVB Leerink | $28 → $27 | Maintains | Market Perform |
| 11/04/2021 | 273.83% | SVB Leerink | $43 → $28 | Maintains | Market Perform |
| 08/05/2021 | 487.45% | HC Wainwright & Co. | $55 → $44 | Maintains | Buy |
| 05/07/2021 | 634.31% | HC Wainwright & Co. | $57 → $55 | Maintains | Buy |
| 03/31/2021 | 634.31% | Credit Suisse | → $55 | Initiates Coverage On | → Outperform |
| 02/25/2021 | 447.4% | SVB Leerink | $50 → $41 | Downgrades | Outperform → Market Perform |
| 02/08/2021 | 661.01% | HC Wainwright & Co. | → $57 | Assumes | → Buy |
| 01/25/2021 | 607.61% | Citigroup | $50 → $53 | Downgrades | Buy → Neutral |
| 01/19/2021 | 887.98% | Raymond James | $60 → $74 | Maintains | Strong Buy |
| 01/12/2021 | 781.17% | SVB Leerink | $45 → $66 | Maintains | Outperform |
| 08/06/2020 | 500.8% | SVB Leerink | → $45 | Initiates Coverage On | → Outperform |
| 07/09/2020 | 620.96% | HC Wainwright & Co. | $60 → $54 | Maintains | Buy |
| 06/02/2020 | 567.56% | Citigroup | $49 → $50 | Maintains | Buy |
| 03/03/2020 | 701.07% | HC Wainwright & Co. | $65 → $60 | Reiterates | → Buy |
| 02/03/2020 | 834.58% | Stifel | $45 → $70 | Maintains | Buy |
| 01/15/2020 | 674.37% | Wells Fargo | $48 → $58 | Maintains | Overweight |
| 01/10/2020 | 714.42% | Wolfe Research | → $61 | Initiates Coverage On | → Outperform |
| 12/09/2019 | 474.1% | JP Morgan | → $43 | Initiates Coverage On | → Neutral |
| 11/25/2019 | 767.82% | HC Wainwright & Co. | → $65 | Initiates Coverage On | → Buy |
| 11/25/2019 | 701.07% | Raymond James | $40 → $60 | Maintains | Strong Buy |
| 11/20/2019 | 540.85% | Guggenheim | → $48 | Initiates Coverage On | → Buy |
| 10/29/2019 | 420.69% | Deutsche Bank | $36 → $39 | Maintains | Buy |
| 09/30/2019 | 434.05% | Raymond James | $36 → $40 | Upgrades | Outperform → Strong Buy |
| 08/30/2019 | 500.8% | Stifel | → $45 | Initiates Coverage On | → Buy |
| 08/27/2019 | 554.21% | Citigroup | $22 → $49 | Maintains | Buy |
| 08/05/2019 | 207.08% | Barclays | $15 → $23 | Maintains | Equal-Weight |
| 07/18/2019 | 353.94% | Deutsche Bank | → $34 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月15日 | 6.81% | HC Wainwright公司 | →$8 | 重申 | 中性→中性 |
| 06/06/2023 | 6.81% | HC Wainwright公司 | →$8 | 重申 | 中性→中性 |
| 2023年05月18日 | 140.32% | 花旗集團 | $17→$18 | 維護 | 買 |
| 05/09/2023 | 153.67% | Stifel | $18→$19 | 維護 | 買 |
| 03/31/2023 | 20.16% | 摩根大通 | $8→$9 | 維護 | 中性 |
| 03/21/2023 | 60.21% | 富國銀行 | →$12 | 假設 | →超重 |
| 03/21/2023 | 6.81% | HC Wainwright公司 | →$8 | 重申 | →中性 |
| 03/10/2023 | 126.97% | 花旗集團 | $21→$17 | 維護 | 買 |
| 03/08/2023 | 113.62% | 古根海姆 | →$16 | 重申 | →購買 |
| 01/24/2023 | 6.81% | HC Wainwright公司 | →$8 | 重申 | →中性 |
| 01/20/2023 | 33.51% | SVB Leerink | $8→$10 | 維護 | 市場表現 |
| 01/04/2023 | 6.81% | HC Wainwright公司 | $10→$8 | 維護 | 中性 |
| 2022年12月22日 | 20.16% | 巴克萊 | $7→$9 | 維護 | 等重 |
| 12/20/2022 | 46.86% | 傑富瑞 | $7.7→$11 | 升級 | 持有→購買 |
| 2022年11月21日 | 33.51% | HC Wainwright公司 | $8→$10 | 維護 | 中性 |
| 11/01/2022 | 6.81% | HC Wainwright公司 | $40→$8 | 評級下調 | 購買→中性 |
| 10/24/2022 | 140.32% | Stifel | $21→$18 | 維護 | 買 |
| 2022年10月21日 | 6.81% | SVB Leerink | $19→$8 | 評級下調 | 跑贏→市場表現 |
| 10/04/2022 | 20.16% | 富國銀行 | $45→$9 | 假設 | →超重 |
| 09/14/2022 | 180.37% | 花旗集團 | $27→$21 | 維護 | 買 |
| 2022年08月26日 | 260.48% | 花旗集團 | $28→$27 | 維護 | 買 |
| 2022年05月27日 | 153.67% | SVB Leerink | $18→$19 | 維護 | 跑贏大盤 |
| 2022年05月23日 | 434.05% | HC Wainwright公司 | $44→$40 | 維護 | 買 |
| 05/09/2022 | 273.83% | 花旗集團 | $30→$28 | 維護 | 買 |
| 05/09/2022 | 273.83% | 花旗集團 | $30→$28 | 維護 | 買 |
| 05/05/2022 | 86.92% | 古根海姆 | →$14 | 升級 | 中性→購買 |
| 03/15/2022 | 100.27% | Evercore ISI集團 | →$15 | 開始承保 | →跑贏大盤 |
| 02/28/2022 | 300.53% | 花旗集團 | $53→$30 | 維護 | 買 |
| 02/09/2022 | 540.85% | 富國銀行 | $56→$48 | 維護 | 超重 |
| 2021年12月10日 | 887.98% | 雷蒙德·詹姆斯 | →$74 | 評級下調 | 強勢買入→跑贏大盤 |
| 2021年12月10日 | - | SVB Leerink | 升級 | 市場表現優於→ | |
| 2021年11月10日 | 260.48% | SVB Leerink | $28→$27 | 維護 | 市場表現 |
| 11/04/2021 | 273.83% | SVB Leerink | $43→$28 | 維護 | 市場表現 |
| 08/05/2021 | 487.45% | HC Wainwright公司 | $55→$44 | 維護 | 買 |
| 05/07/2021 | 634.31% | HC Wainwright公司 | $57→$55 | 維護 | 買 |
| 03/31/2021 | 634.31% | 瑞士信貸 | →$55 | 開始承保 | →跑贏大盤 |
| 02/25/2021 | 447.4% | SVB Leerink | $50→$41 | 評級下調 | 跑贏→市場表現 |
| 02/08/2021 | 661.01% | HC Wainwright公司 | →$57 | 假設 | →購買 |
| 2021/01/25 | 607.61% | 花旗集團 | $50→$53 | 評級下調 | 購買→中性 |
| 2021/01/19 | 887.98% | 雷蒙德·詹姆斯 | $60→$74 | 維護 | 強勢購買 |
| 2021/12/01 | 781.17% | SVB Leerink | $45→$66 | 維護 | 跑贏大盤 |
| 08/06/2020 | 500.8% | SVB Leerink | →$45 | 開始承保 | →跑贏大盤 |
| 07/09/2020 | 620.96% | HC Wainwright公司 | $60→$54 | 維護 | 買 |
| 06/02/2020 | 567.56% | 花旗集團 | $49→$50 | 維護 | 買 |
| 03/03/2020 | 701.07% | HC Wainwright公司 | $65→$60 | 重申 | →購買 |
| 02/03/2020 | 834.58% | Stifel | $45→$70 | 維護 | 買 |
| 2020/01/15 | 674.37% | 富國銀行 | $48→$58 | 維護 | 超重 |
| 2020/10/01 | 714.42% | 沃爾夫研究 | →$61 | 開始承保 | →跑贏大盤 |
| 2019年12月09日 | 474.1% | 摩根大通 | →$43 | 開始承保 | →中性 |
| 2019年11月25日 | 767.82% | HC Wainwright公司 | →$65 | 開始承保 | →購買 |
| 2019年11月25日 | 701.07% | 雷蒙德·詹姆斯 | $40→$60 | 維護 | 強勢購買 |
| 2019年11月20日 | 540.85% | 古根海姆 | →$48 | 開始承保 | →購買 |
| 2019年10月29日 | 420.69% | 德意志銀行 | $36→$39 | 維護 | 買 |
| 2019年09月30日 | 434.05% | 雷蒙德·詹姆斯 | $36→$40 | 升級 | 跑贏→強勢買入 |
| 2019年08月30日 | 500.8% | Stifel | →$45 | 開始承保 | →購買 |
| 2019年08月27日 | 554.21% | 花旗集團 | $22→$49 | 維護 | 買 |
| 2019年08月05日 | 207.08% | 巴克萊 | $15→$23 | 維護 | 等重 |
| 2019年07月18日 | 353.94% | 德意志銀行 | →$34 | 開始承保 | →購買 |
What is the target price for Zymeworks (ZYME)?
Zymeworks的目標價是多少？
The latest price target for Zymeworks (NASDAQ: ZYME) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $8.00 expecting ZYME to rise to within 12 months (a possible 6.81% upside). 21 analyst firms have reported ratings in the last year.
HC Wainwright&Co.於2023年8月15日報道了Zymeworks(納斯達克代碼：ZYME)的最新目標價。這家分析公司將目標價定為8.00美元，預計ZYME將在12個月內上漲(可能上漲6.81%)。去年有21家分析公司公佈了評級。
What is the most recent analyst rating for Zymeworks (ZYME)?
Zymeworks的最新分析師評級是多少？
The latest analyst rating for Zymeworks (NASDAQ: ZYME) was provided by HC Wainwright & Co., and Zymeworks reiterated their neutral rating.
分析師對Zymeworks(納斯達克代碼：ZYME)的最新評級由HC Wainwright&Co.提供，Zymeworks重申其中性評級。
When is the next analyst rating going to be posted or updated for Zymeworks (ZYME)?
Zymeworks的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zymeworks, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zymeworks was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Zymeworks的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Zymeworks的上一次評級是在2023年8月15日提交的，因此您應該預計下一次評級將在2024年8月15日左右提供。
Is the Analyst Rating Zymeworks (ZYME) correct?
分析師對Zymeworks的評級正確嗎？
While ratings are subjective and will change, the latest Zymeworks (ZYME) rating was a reiterated with a price target of $0.00 to $8.00. The current price Zymeworks (ZYME) is trading at is $7.49, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但Zymeworks(Zymeworks)的最新評級被重申為目標價在0.00美元至8.00美元之間。Zymeworks目前的交易價格為7.49美元，在分析師的預測範圍內。